China hits Swiss pharma company with RPM fine

China’s antitrust authority has fined the local subsidiary of Swiss pharmaceutical company Geistlich Pharma €1.3 million for dictating resale prices for a pair of products used in dental implants over a 12-year period.

Get unlimited access to all Global Competition Review content